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Abstract
Background: MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies have shown 
altered expression levels of several microRNAs in renal cell carcinoma.
Methods: We examined the expression levels of selected microRNAs in 38 samples of conventional renal cell 
carcinoma (RCC) and 10 samples of non-tumoral renal parenchyma using TaqMan real-time PCR method.
Results: The expression levels of miRNA-155 (p < 0.0001), miRNA-210 (p < 0.0001), miRNA-106a (p < 0.0001) and 
miRNA-106b (p < 0.0001) were significantly over-expressed in tumor tissue, whereas the expression of miRNA-141 (p < 
0.0001) and miRNA-200c (p < 0.0001) were significantly decreased in RCC samples. There were no significant 
differences between expression levels of miRNA-182 and miRNA-200b in tumor samples and renal parenchyma. Our 
data suggest that expression levels of miRNA-106b are significantly lower in tumors of patients who developed 
metastasis (p = 0.030) and miR-106b is a potential predictive marker of early metastasis after nephrectomy in RCC 
patients (long-rank p = 0.032).
Conclusions: We have confirmed previous observations obtained by miRNA microarray analysis using standardized 
real-time PCR method. For the first time, we have identified a prognostic significance of miRNA-106b, which, after 
validation on a larger group of patients, maybe useful as a promising biomarker in patients with RCC.
Background
Renal cell carcinoma (RCC) accounts for approximately
3 %  o f  c a n c e r s  i n  a d u l t s  a s  w e l l  a s  8 5 %  o f  a l l  p r i m a ry
malignant kidney tumors. It is the third most common
urological cancer after prostate and bladder cancer but it
has the highest mortality rate at over 40% [1,2]. Clear cell
(conventional) carcinoma is the most common subtype of
RCC and accounts for approximately 75-80% of these
tumors [3]. Apart from surgery, it is both chemotherapy
and radiotherapy resistant. The present absence of bio-
markers for early detection and follow-up of the disease is
responsible for late diagnosis and subsequent poor prog-
nosis. It is necessary, therefore, to improve our under-
standing of RCC's pathogenesis, identify new biomarkers
enabling prediction of early metastasis after nephrec-
tomy, and develop new targeted therapies.
One of the most modern and progressive approaches
for molecular characterization of tumors today is based
on microRNA expression profiles. MicroRNAs (miRNAs)
are short noncoding RNAs, 18-25 nucleotides in length,
that post-transcriptionally regulate gene expression.
Depending upon the extent of their complementarity
with target mRNA, miRNAs act by two mechanisms of
post-transcriptional regulation of gene expression, which
lead to target mRNA degradation or repression of its
translation and consequent decrease of particular protein
levels. Bioinformatics have predicted that miRNAs have
the capacity to regulate one third of all mammalian genes,
among which are included a significant number of impor-
tant oncogenes and tumor suppressor genes [4,5]. MiR-
NAs have been studied most intensively in the field of
oncological research, and emerging evidence suggests
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that altered miRNA regulation is involved in the patho-
genesis of cancer [6-8]. Changes in the expression of miR-
NAs have been observed in a variety of human cancers
[9-11].
Several studies have focused on miRNAs' significance
in RCC [12]. These papers described the potential of
miRNA profiles to distinguish tumor tissue from normal
renal parenchyma [13-20], classify renal cell carcinomas
according to histological subtypes [13-15], identify
expression profiles to predict metastasis from primary
tumors [13,16], and determine prognosis for particular
renal cell carcinoma patients [13,16]. Most of these stud-
ies have been methodologically based on hybridization
microarray platforms and mostly included only small
numbers of patients. Nevertheless, there exists a certain
intersection between groups of miRNAs identified in
individual studies, and several interesting mechanistic
studies have revealed the functions of some miRNAs in
vitro [21].
The aim of our study was to validate expression
changes of selected miRNAs identified in previous
microarray studies (miR-155 [16], miR-106a [19], miR-
106b [19], miR-200b [16,19], miR-200c [15,16,19], miR-
141 [15,16], miR-182 [13] and miR-210 [16,19]) by the
standardized and more quantitative method that is real-
time polymerase chain reaction (PCR). For the first time,
we have correlated miRNAs with the relapse-free survival
of RCC patients in order to evaluate them as potential
predictive biomarkers of early metastasis after nephrec-
tomy.
Patients and methods
Study population
Thirty-eight patients (24 men, 14 women) diagnosed for
clear cell renal cell carcinoma at Masaryk Memorial Can-
cer Institute (Brno, Czech Republic) between 2003 and
2009 were included in this study. The study has been
approved by the local Ethical Committee. Patients' ages
ranged between 41 and 89 years, with a median of 68.
Histological diagnosis was established according to the
guidelines of the World Health Organization. Cases were
selected according to tissue availability and were not
stratified for any known preoperative or pathological
prognostic factor. Clinical follow-up data in the form of
annually assessed survival time was available for all
patients. The median follow-up time for all cases was 40
months and ranged from 3 to 105 months. Clinical char-
acteristics of the patients are summarized in Table 1.
Tissue sample preparation and miRNA purification
Under the supervision of an experienced pathologist, 48
tissue samples were collected (before any treatment was
started) from surgically resected tissues - 38 samples
from primary tumors and 10 from adjacent non-tumoral
renal parenchyma. All samples were immediately stored
in liquid nitrogen until RNA extraction. Samples were
homogenized (Retch MM301) in sterile conditions before
total RNA isolation. Total RNA isolation and small RNA
enrichment procedures were performed using the mir-
Vana miRNA Isolation Kit (Ambion, USA) according to
the manufacturer's instructions. DNA was extracted
using the Qiagen DNA Mini Kit (Qiagen, Germany),
again following the manufacturer's instructions. Nucleic
acid concentration and purity were controlled by UV
spectrophotometry (A260:A280 > 2.0; A260:A230 > 1.8)
using a Nanodrop ND-1000 (Thermo Scientific, USA).
Real-time quantification of miRNAs by stem-loop RT-PCR
Complementary DNA (cDNA) was synthesized from
total RNA using gene-specific primers according to the
TaqMan MicroRNA Assay protocol (PE Applied Biosys-
tems, Foster City, Calif., USA). Reverse transcriptase (RT)
reactions utilized 10 ng of RNA sample, 50 nM of stem-
loop RT primer, 1 × RT buffer and 0.25 mM each of
dNTPs, 3.33 U/μl MultiScribe RT and 0.25 U/μl RNase
inhibitor (all from the TaqMan MicroRNA Reverse Tran-
scription kit of Applied Biosystems; 4366597). Reaction
mixtures (15 μl) were incubated in a TGradient thermal
cycler (Biometra) for 30 min at 16°C, 30 min at 42°C, 5
min at 85°C, and then held at 4°C. Real-time PCR was
performed using the Applied Biosystems 7500 Sequence
Table 1: Patient characteristics
Factor Number
Age
mean 68
range 41-89
Sex
male 24
female 14
Stage
T1+T2 19
T3 19
Fuhrman grade
G1 6
G2 25
G3 7
Early recurrence
Yes* 15
No** 23
* Recurrence-free survival = 11.5 (5-36) months
** Follow-up = 50 (41-62) months
Medians and 25th and 75th percentiles in parentheses.Slaby et al. Journal of Experimental & Clinical Cancer Research 2010, 29:90
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Detection System. The 20-μl PCR reaction mixture
included 1.3 μl of RT product, 1 × TaqMan (NoUmpErase
UNG) Universal PCR Master Mix, and 1 μl of primer and
probe mix of the TaqMan MicroRNA Assay protocol (PE
Applied Biosystems). Reactions were incubated in a 96-
well optical plate at 95°C for 10 min, followed by 40 cycles
at 95°C for 15 s and 60°C for 10 min. The threshold cycle
data were determined using the default threshold set-
tings. All real-time PCR reactions were run in triplicate
and average threshold cycle (CT) and SD values were cal-
culated.
Data normalization and statistical analysis
Expression data were normalized according to expression
of the RNU6B reference DNA (Assay No. 4373381;
Applied Biosystems). Statistical differences between
miRNA levels in RCCs and RP and differences in therapy
r e s p o n s e  i n  r e l a t i o n  t o  m i R N A  l e v e l s  w e r e  e v a l u a t e d
using the nonparametric Mann-Whitney U test between
2 groups. Survival analyses were performed using the
long-rank test and Kaplan-Meier plots approach. All cal-
culations were performed using Statistica software ver-
sion 6.0 (StatSoft Inc., USA).
Results
We identified gene expression levels of the studied miR-
NAs in 38 RCCs and 10 non-tumoral renal parenchyma
(RP). Differences between the two groups were evaluated
using the Mann-Whitney test and also by the Wilcoxon
test for ten paired samples. Both methods identified
highly significant differences between RCC and RP in the
expression levels of the most studied miRNAs. Signifi-
cance levels and medians of the relative expression values
with their ranges defined by the 25th and 75th percentiles
are presented in Table 2. The real-time PCR analysis indi-
cated no significant difference between RCC and the RP
in expression levels of miR-200b and miR-182. By con-
trast, the expression levels of miR-155, miR-210, miR-
106a and miR-106b were significantly upregulated in the
tumor compared to the RP. The most significant differ-
ence was seen for miR-210, for which the expression lev-
els were more than 60 times higher in RCC tissue.
Conversely, miR-141 and miR-200 were significantly
downregulated in RCCs (Table 2). The most significant
difference was observed in miR-141, with levels in RCCs
approximately 15 times lower than in the RP.
To evaluate the potential association of individual miR-
NAs with the prognosis of RCC patients after nephrec-
tomy, the expression levels of each miRNA in the group
of patients who developed metastasis were compared
with their levels in the group of patients in remission.
Metastatic patients tended to have lower levels of miR-
155, miR-106a and miR-106b in RCCs, but only miR-
106b reached statistical significance (p = 0.03) (Table 3).
To determine differences for relapse-free survival on the
basis of miR-106b expression, Kaplan-Meier plots were
constructed and the long-rank test was performed. This
analysis demonstrated significant difference (p = 0.032).
On the other hand, no association was found between the
development of metastasis and miR-155, miR-210, miR-
106a, miR-200b and miR-200c (Table 3).
Discussion
It has become evident that genomic information for tran-
scribing miRNAs is implemented in the human genome,
and miRNAs constitute a robust regulatory network with
post-transcription regulatory efficiency for almost one
third of human coding genes. A number of different
approaches to quantifying miRNAs in tumors and non-
tumoral tissue have been described, including microar-
rays, modified invader assay, bead-based flow cytometric
assay, and real-time PCR [11]. The main advantage of
real-time PCR is the fact that it is a more quantitative and
more sensitive method compared with other high-
throughput assays. In our study, we have analyzed expres-
sion levels of selected miRNAs previously identified by
global miRNA profiling studies in RCC clinical speci-
mens as suspected diagnostic biomarkers using a stan-
d a r d i z e d  T a q M a n  r e a l - t i m e  P C R  a p p r o a c h  o n  a  l a r g e r
group of RCC patients. This validation is necessary if one
is to draw conclusions from the findings derived from
hybridization microarray analysis.
One of the most frequently studied miRNAs in cancer
biology, miR-155, has repeatedly been identified through
miRNA microarray profiling as upregulated also in RCC
tissue [15,16]. We have confirmed observations from
these studies, inasmuch as miR-155 levels were almost 30
times higher in RCCs compared to RP. The available
experimental evidence indicates that miR-155 is over-
expressed in a variety of malignant tumors (breast, lung,
colon, head/neck), which allows us to include this miRNA
into the list of oncogenic miRNAs with high importance
in cancer diagnosis and prognosis [22].
Three miRNA microarray studies have revealed down-
regulation of miR-141 and miR-200c in RCC tissue
[15,16,18]. In agreement with these results, we have
observed 20 times higher levels of miR-141 and 10 times
higher levels of miR-200c in RP compared to RCCs. Both
miR-200c and miR-141 are members of the miR-200 fam-
ily that is mechanistically associated with the process of
epithelial-mesenchymal transition (EMT). EMT is char-
acterized by a decrease of E-cadherin, loss of cell adhe-
sion, and increased cell motility leading to promotion of
metastatic behavior of cancer cells (including RCC) [23].
A molecular link between EMT and the miR-200 family is
represented by zinc-finger E-box binding homeobox 1
(ZEB1), a crucial inducer of EMT in various human
tumors directly suppressing transcription of miR-141 andSlaby et al. Journal of Experimental & Clinical Cancer Research 2010, 29:90
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miR-200c, which strongly activate epithelial differentia-
tion in pancreatic, colorectal and breast cancer cells [24].
On the other hand, ZFHX1B, also known as ZEB2 and
Smad-interacting protein 1 (SIP1), was identified as the
common target of miR-141 and miR-200c. It already has
been reported that ZFHX1B is upregulated in a variety of
human carcinomas and that it may function as a tran-
scriptional repressor for E-cadherin [23].
Huang et al. [20] have described induction of miR-210
expression under the hypoxic conditions dependent on
HIF-α expression. Mutations in the VHL gene, one of the
key events in RCC pathogenesis, is associated with accu-
mulation of HIF-α. Consistent with these findings and
with previous profiling studies [16,19,20], we have
observed more than 60 times higher levels of miR-210 in
tumors.
We have identified significant upregulation of miR-
106a and miR-106b in RCCs with approximately 4 and 5
times higher levels, respectively. Our data are in agree-
ment with the results of Chow et al. [21], who used an
approach based on real-time PCR. Interestingly, miR-
106a and mirR-106b upregulation has not been detected
by any other group focused on miRNA profiling in RCC
[13-18], probably due to the lower sensitivity and lower
dynamic range of hybridization-based microarrays. Over-
expression of miR-106b, however, has been observed in a
variety of human tumors, including colorectal cancer
[25], gastric cancer [26], hepatocellular carcinoma [27]
and head and neck squamous cell carcinomas [28].
We have not confirmed significant differences in miR-
182 and miR-200b levels between RCCs and RP as
reported by Petillo et al. [13], Jung et al. [16] and Chow et
al. [19].
To date, only one study was done focusing on miRNAs'
significance in RCC prognosis, and that involved a group
of 8 RCC patients (4 patients indicated good and 4 poor
prognosis) [13]. Petillo et al. [13] identified a group of 20
miRNAs enabling classification of RCC patients accord-
ing to their prognosis. We have tested only one (miR-182)
of these 20 miRNAs and have not proven its prognostic
significance. Moreover, other analyzed miRNAs were
evaluated as possible prognostic factors enabling the pre-
diction of early metastasis after nephrectomy, and, except
for miR-106b, none of these indicated significant poten-
tial to predict prognosis. Surprisingly, miR-106b, consid-
ered to be oncogenic [29], has significantly higher
expression levels in RCC of patients with better progno-
sis. A possible explanation for this contradiction lies in
the involvement of the miR-106b family (miR-106b, miR-
93, and miR-25) in TGF-β signaling [30]. The role of
TGF-β signaling in cancer pathogenesis is characteristi-
cally ambiguous [31]. In the early events of carcinogene-
Table 2: Expression levels of selected miRNAs in renal cell carcinoma (RCC) in comparison to renal parenchyma (RP)
non-paired samplesp a i r e d  s a m p l e s
RCC RP p-value RCC RP p-value
n = 38 n = 10 n = 10 n = 10
miRNA-155 12.261* 0.430 < 0.0001 17.882 0.430 0.002
3.945-24.127** 0.180-0.811 9.234-30.451 0.179-0.811
miRNA-141 0.107 1.937 0.002 0.296 1.937 0.004
0.047-0.630 1.128-2.805 0.107-1.235 1.128-2.805
miRNA-210 38.947 0.592 < 0.0001 28.264 0.592 0.002
25.153-74.817 0.488-0.701 7.750-73.600 0.488-0.701
miRNA-200c 0.268 2.41 < 0.0001 0.259 2.41 0.002
0.171-0.508 1.910-3.408 0.171-0.565 1.910-3.408
miRNA-106a 20.557 4.934 < 0.0001 22.846 4934 0.004
13.302-31.403 3.857-7.910 13.302-28.127 3.857-7.910
miRNA-106b 14.102 2.937 < 0.0001 16.356 2973 0.002
8.807-20.746 1.941-3.963 12.101-30.239 1.942-3.963
miRNA-200b 7.384 5.702 0.559 5.756 5702 0.846
3.599-15.578 4.715-8.260 1.892-9.571 4.715-8.260
miRNA-182 0.147 0.121 0.919 0.19 0.121 0.322
0.047-0.515 0.086-0.154 0.038-0.491 0.086-0.154
* Medians of expression level related to RNU6B with **25th and 75th percentiles.Slaby et al. Journal of Experimental & Clinical Cancer Research 2010, 29:90
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Table 3: Expression levels in RCC of patients with/without development of metastatic disease
Metastatic disease Relapse-free disease p-value
n = 15 n = 23
miRNA-155 6.07* 15.58 0.095
1.80-21.03** 7.29-27.58
miRNA-141 0.072 0.102 0.682
0.033-0.671 0.046-0.181
miRNA-210 36.758 41.137 0.317
12.147-62.417 28.581-82.332
miRNA-200c 0.266 0.301 0.502
0.108-0.487 0.185-0.517
miRNA-106a 14.522 25.126 0.081
12.469-24.862 16.923-42.519
miRNA-106b 10.387 16.451 0.030
6.591-15.950 11.119-25.831
miRNA-200b 6.556 7.804 0.87
3.849-14.096 3.697-14.676
miRNA-182 0.302 0.081 0.194
0.051-0.728 0.036-0.321
* Medians of expression level related to RNU6B with **25th and 75th percentiles.
Figure 1 Comparison of miR-155, miR-210, miR-106a and miR-106b expression levels in renal parenchyma (RP) and renal cell carcinomas 
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sis, TGF-β levels are lower and indicate features of a
tumor suppressor, but in the late phase, within the devel-
opment of metastatic disease, the degree of TGF-β activa-
tion increases and leads to the promotion of
immunosuppression, neoangiogenesis and progression of
the disease. In relation to the TNM stage of RCCs, we
have observed a general tendency for miR-106b levels to
decrease from earlier stages towards advanced. Higher
levels of miR-106b in selected RCCs may be connected
with anti-neoplastic effects due to interference with TGF-
β signaling.
Conclusions
To our knowledge, this is the first report observing that
the expression of miR-106b has a correlation with the
development of metastasis and relapse-free survival in
RCC patients after nephrectomy. Our findings also sup-
port the importance of miR-155, mR-210, miR-106a,
miR-106b, miR-200c and miR-141 in RCC pathogenesis.
While further studies and validations are needed, we sug-
gest that miRNA-106b might be used for predicting early
metastasis after nephrectomy in clinical practice. If vali-
dated, this would represent a next step to better treat-
ment decisions and, ultimately, improvement in the
survival rate of RCC patients.
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